NCT01960374View on ClinicalTrials.gov

Dose-escalation Study to Assess Selumetinib Safety, Tolerability and PK

PHASE1CompletedINTERVENTIONAL
Enrollment

117

Participants

Timeline

Start Date

October 31, 2013

Primary Completion Date

May 31, 2014

Study Completion Date

May 31, 2014

Conditions
Healthy Volunteers Pharmacokinetic Study
Interventions
DRUG

Selumetinib

1, 2 or 3 x 25 mg selumetinib (AZD6244; ARRY-142886) (Hyd-Sulfate) capsule administered orally as a single dose on Day 1 of the study (total dose 25 mg, 50 mg and 75 mg respectively) with 240 ml of water at room temperature.

Trial Locations (1)

Unknown

Research Site, London

Sponsors

Lead Sponsor

AstraZeneca
All Listed Sponsors
lead

AstraZeneca

INDUSTRY